4th Quarter - Report
BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC for BOEHRINGER INGELHEIM USA CORPORATION
Firm
Income
—
Expenses
$590,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Animals ANI
Illegal Compounding
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY CHEVALIER EFANTIS | — |
| ALANNA PORTER TEMME | — |
Pharmacy PHA
Drug Shortages; The Preserving Access to Life Saving Medicines Act (S. 296)
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY CHEVALIER EFANTIS | — |
| JONATHAN REA MCPHERSON | — |
| PAUL ROMNESS | — |
| ALANNA PORTER TEMME | — |
Health Issues HCR
Gain Act; Shortages; Supply Chain Security; Best Pharmaceuticals for Children Act/Pediatric Research Equity Act Reauthorization; Risk Evaluation and Mitigation Strategies (REMS); Generic Drug User Fee Act; Prescription Drug User Fee Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY CHEVALIER EFANTIS | — |
| JONATHAN REA MCPHERSON | — |
| ALANNA PORTER TEMME | — |
Budget/Appropriations BUD
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Fiscal Cliff
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY CHEVALIER EFANTIS | — |
| JONATHAN REA MCPHERSON | — |
| ALANNA PORTER TEMME | — |
Copyright/Patent/Trademark CPT
Patent Settlements
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY CHEVALIER EFANTIS | — |
| JONATHAN REA MCPHERSON | — |
| PAUL ROMNESS | — |
| ALANNA PORTER TEMME | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.